HUTCHMED (China) (HMDCF) Cash & Equivalents (2014 - 2025)

HUTCHMED (China) (HMDCF) has 12 years of Cash & Equivalents data on file, last reported at $175.8 million in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $175.8 million, up 63.46% year-over-year; the trailing twelve-month figure through Dec 2025 was $175.8 million (up 63.46% YoY), and the FY2025 annual result was $71.3 million, down 74.85% from the prior year.
• Cash & Equivalents grew to $175.8 million in Q4 2025 per HMDCF's latest filing, from $110.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $467.5 million in Q2 2022 and troughed at $113433.7 in Q4 2023.
• A 5-year average of $194.6 million and a median of $175.8 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 99.86% in 2023, then jumped 94712.72% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $129.9 million in 2021, then tumbled by 37.89% to $80.7 million in 2022, then tumbled by 99.86% to $113433.7 in 2023, then jumped by 94712.72% to $107.5 million in 2024, then surged by 63.46% to $175.8 million in 2025.
• Business Quant data shows HMDCF's Cash & Equivalents at $175.8 million in Q4 2025, $110.7 million in Q2 2025, and $107.5 million in Q4 2024.